H.C. Wainwright raised the firm’s price target on Ocular Therapeutix to $15 from $12 and keeps a Buy rating on the shares following the Q4 report. The company’s sales grew 13.5% in 2023 and multiple clinical catalysts are expected in 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix reports Q4 EPS (35c), consensus (30c)
- Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
- Ocular Therapeutix options imply 11.5% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 11, 2024
- Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
